Chemicals company, BASF, has reformulated an active delivery product, enabling it to adhere to the regulations of Japanese “quasi drugs”, opening up potential for formulators to target the Japanese skin whitening market.
According to BASF, the original product, Cytovector, intelligently penetrates the cell membrane, allowing it to aid the delivery of active ingredients, such as anti-wrinkle creams and skin whitening products. The new formulation, Cytovector QD, has had one of the ingredients, quaternised soy protein, removed and replaced with another ingredient with similar efficacy, but which is listed with the Japanese Standard of Quasi-Drug Ingredients.
